Agentix Corp.

Agentix Corp

Company snapshot

• Incorporated in Nevada on April 18, 2013
• Fiscal year end: March 31
• Business focus: clinical development-stage pharmaceuticals for metabolic diseases, specializing in peripherally-restricted CB1 receptor antagonists
• Current stage: development-focused; has not generated meaningful revenues to date

Corporate history and structure

• Name change: FairWind Energy, Inc. → Agentix Corp. on June 17, 2019
• 2020 share exchange: On June 1, 2020 the company issued 27,932,271 shares to acquire all issued and outstanding shares of GSL Healthcare, Inc.; former GSL Healthcare shareholders hold approximately 88% of the issued common stock; GSL Healthcare became a wholly owned subsidiary
• Australia subsidiary: Agentix Australia Pty Ltd established September 2022 to conduct development activities and participate in a 43.5% Australian tax rebate program for biotech/pharma development costs
• Executive operations: As of March 31, 2026 the company had no full-time or part-time employees; the business is operated by Rehan Huda, one of two directors
• Primary address: 32932 Pacific Coast Highway, #14-254, Dana Point, California 92629 (virtual office)

Key assets, licensing, and pipeline

• AGTX-2004 (DBPR211)

  • Peripherally-acting CB1 receptor antagonist; evidence of efficacy in animal models and does not cross the blood-brain barrier
  • IND cleared by the FDA
  • Phase 1 safety and tolerability dose-escalation study planned to commence under Agentix Australia Pty Ltd
  • Worldwide exclusive license with National Health Research Institutes (NHRI) granted March 21, 2021; effective May 21, 2021
  • License economics: upfront license and document delivery fees; 16 milestone payments through Phase III and regulatory approvals; royalties of 4% of net sales; ongoing annual license fee and quality/stability testing fees; license term extends until the last licensed patent rights and market approvals expire on a country-by-country basis (patent terms up to 20 years)

• AGTX-2003 (RTI-1092769)

  • Peripherally-acting CB1 receptor inverse agonist; demonstrated efficacy in animal models of obesity and NAFLD
  • Additional enabling animal studies in preparation for FDA IND
  • Exclusive worldwide license with Research Triangle Institute (RTI) granted March 16, 2020
  • License economics include development milestones and royalties on sales after market authorization

• ABP-2003

  • Exclusive worldwide license with RTI granted May 16, 2020 (license effective March 16, 2020; notice of effectiveness May 21, 2021)
  • Scope: pyrazole compounds for treating Type 2 diabetes, obesity, and fatty liver disease; royalties and milestones apply

Strategic orientation

• Primary focus on developing two peripherally-restricted assets targeting metabolic syndrome
• Plan to partner with larger biopharma companies for pivotal development and commercialization stages
• Development activities managed through Agentix Australia Pty Ltd

Intellectual property posture

• Relies on licensed patents and underlying technology, trade secrets, confidentiality provisions, and contractual protections
• The company holds exclusive licenses covering AGTX-2004, AGTX-2003, and ABP-2003

Regulatory and market context

• Products are subject to U.S. FDA and international regulatory processes, including INDs, Phase I/II/III trials, manufacturing licensing, and post-approval obligations
• License agreements include milestones, royalties, and ongoing regulatory/compliance fees
• The biopharma landscape is competitive and globally distributed, with peripherally-restricted CB1 strategies intended to avoid central nervous system adverse effects

Financial highlights (selected)

• Research and development costs:
  • FY ended March 31, 2026: $125,079
  • FY ended March 31, 2025: $180,987
• Revenues: the company has not generated meaningful revenues to date
• Employees: 0 full-time or part-time employees as of March 31, 2026
• R&D activity is managed through the Australian subsidiary and under external license agreements

Properties and facilities

• No real property leased or owned; operates from a virtual office
• Executive office address: 32932 Pacific Coast Highway, Dana Point, California 92629
• Telephone: (321) 299-2014

Legal proceedings

• No current material legal proceedings reported

Summary

Agentix Corp is a Nevada-based, development-stage biopharma company focused on peripherally-restricted CB1 receptor antagonists for metabolic diseases. Its two lead assets, AGTX-2004 and AGTX-2003, are under exclusive worldwide licenses from NHRI and RTI, respectively. The company completed a share exchange in 2020 that brought GSL Healthcare into the group and established Agentix Australia Pty Ltd in 2022 to support development activities and access Australian R&D incentives. The business has recorded modest R&D spending and operates without employees, managing development through its Australian subsidiary and external partners.